10.1038/s41386-018-0150-5 - Isoform-selective phosphoinositide 3-...

This document has been corrected

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

10.1038/s41386-018-0150-5

Published Online: 2018-07-13

Journal: Neuropsychopharmacology•Publisher: Springer Science and Business Media LLC

Authors: A. G. Allen•Angela R. White•Anwesha Banerjee•Christina Gross•Durgesh Tiwari•Eric Klann•Francesco Longo•Gary J. Bassell•Joseph C. Krzeski•Lindsay M. Schroeder-Carter•Nada A. Elsayed•Ralph A. Rivero•Rosemary Puckett•Shannon L. Gourley

This document has been corrected

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

10.1038/s41386-018-0150-5

Published Online: 2018-07-13

Journal: Neuropsychopharmacology

NOW

2022-06-14•Correction

Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

10.1038/s41386-022-01345-x

* information provided by CrossRef

2022-06-14•Correction

10.1038/s41386-022-01345-x

* information provided by CrossRef

2018-07-13•Published

2022-06-14•Correction

Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

10.1038/s41386-022-01345-x

* information provided by CrossRef

This document has been corrected

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

10.1038/s41386-018-0150-5

Published Online: 2018-07-13

Journal: Neuropsychopharmacology•Publisher: Springer Science and Business Media LLC